Cheryl Moore, MD | |
789 Central Ave, Dover, NH 03820-2526 | |
(603) 742-2132 | |
Not Available |
Full Name | Cheryl Moore |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 789 Central Ave, Dover, New Hampshire |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356332670 | NPI | - | NPPES |
11098339 | Other | CAQH# | |
30203266 | Medicaid | NH | |
110033126A | Medicaid | MA | |
305920099 | Medicaid | ME |
Mailing Address | Practice Location Address |
---|---|
Cheryl Moore, MD 680 Centre Street, Pathology Department, Brockton, MA 02301-3308 Ph: (508) 941-7000 | Cheryl Moore, MD 789 Central Ave, Dover, NH 03820-2526 Ph: (603) 742-2132 |
News Archive
The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease - the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.
A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
While research has shown that poor cardiovascular health can damage blood flow to the brain increasing the risk for dementia, a new study led by UC San Francisco indicates that poor mental health may also take its toll on cognition.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
› Verified 8 days ago
David A Novis, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-2132 | |
Glenn Harold Littell, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-2132 | |
Dr. Polius Raslavicius, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Wentworth-douglass Hospital, Dover, NH 03820 Phone: 603-335-2338 | |
Dr. Lucy Harn Kapur, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-5252 |